苏氨酸对接法合成利拉鲁肽

doi:10.7503/cjcu20180350

摘要/Abstract

摘要：

通过苏氨酸对接的策略实现片段组氨酸¹-甘氨酸⁴(His¹-Gly⁴)与片段苏氨酸⁵-甘氨酸³¹(Thr⁵-Gly³¹)的连接, 有效避免了利拉鲁肽N端氨基酸偶联效率低的问题; 再通过控制pH值的方法, 选择性地将赖氨酸²⁰(Lys²⁰)侧链修饰基团引入到未保护的肽链上. 此方法每步均有良好的化学选择性, 片段对接的收率达76.4%, 且反应条件温和, 具有较好的应用前景.

关键词: 利拉鲁肽, 苏氨酸对接, 侧链修饰

Abstract:

A new method for the synthesis of liraglutide was reported, using threonine ligation to couple the segment histidine¹-glycine⁴and the segment threonine⁵-glycine³¹. This method addressed the problem of low coupling efficiency at N-terminal residuals of liraglutide. The lysine²⁰ side-chain modification group was directly introduced onto the unprotected linear peptide by controlling pH of the solution. The ligation reaction was achieved with 76.4% overall yield. This new method is featured with the advantages of high chemoselectivity and mild reaction conditions, and has a potential of industrial application.

Key words: Liraglutide, Threonine ligation, Side-chain modification

中图分类号:

O629.72

TrendMD:

范佳辉, 卞亚楠, 苏贤斌. 苏氨酸对接法合成利拉鲁肽. 高等学校化学学报, 2018, 39(12): 2679.

FAN Jiahui,BIAN Yanan,SU Xianbin. Synthesis of Liraglutide Through Threonine Ligation^†. Chem. J. Chinese Universities, 2018, 39(12): 2679.

图/表 8

Fig.1 Structure of liraglutide

Scheme 1 Model reaction of Gly and Thr

Scheme 2 Synthesis routes of liraglutide

Table 1 Appearance, melting points and optical rotation for compounds 1—12

Compd.	Appearance	m. p./℃	[α $] D 20$ /(°) (c 1, CHCl₃)	Compd.	Appearance	m. p./℃	[α $] D 20$ /(°) (c 1, CHCl₃)
1	White solid	129.4—130.3		7	Pale yellow oil
2	Pale yellow solid	78.2—80.0	-33.5	8	White solid
3	White solid	95.6—97.3	-27.2	9	White solid
4	Pale yellow oil			10	White solid
5	White solid			11	Pale yellow oil
6	White solid			12	White solid	64.5—65.7	-15.2

Table 1 Appearance, melting points and optical rotation for compounds 1—12

Compd.	Appearance	m. p./℃	[α $] D 20$ /(°) (c 1, CHCl₃)	Compd.	Appearance	m. p./℃	[α $] D 20$ /(°) (c 1, CHCl₃)
1	White solid	129.4—130.3		7	Pale yellow oil
2	Pale yellow solid	78.2—80.0	-33.5	8	White solid
3	White solid	95.6—97.3	-27.2	9	White solid
4	Pale yellow oil			10	White solid
5	White solid			11	Pale yellow oil
6	White solid			12	White solid	64.5—65.7	-15.2

Table 2 1H NMR and ESI-MS data for compounds 1—12

Compd.	¹H NMR(400 MHz, CDCl₃), δ	ESI-MS, m/z
1	10.05(s, 1H, CHO), 7.90—7.21(m, 12H, PhH), 5.42(s, 1H, NH), 4.46(d,J=6.8 Hz, 2H, OCH₂), 4.39(d, J=6.8 Hz, 2H, NCH₂CO), 4.26(t, J=7.2 Hz, 1H, PhCHPh)	424.6[M+Na]⁺
2	7.75—6.85(m, 17H, PhH), 6.45(s, 1H,NH), 5.54[s, 1H, NCH(Ph)O], 5.28(q, J=11.5 Hz, 2H, PhCH₂O), 4.36—3.77(m, 6H, OCH₂+NCH₂CO+PhCHPh, OCH), 3.14(d, J=17.2 Hz, 1H, NCHCO), 1.49(d, J=6.0 Hz, 3H, CH₃)	593.2[M+H]⁺
3	8.10(br, 3H, CONH+OH), 7.75—7.25(m, 13H, PhH), 5.18(s, 2H, PhCH₂O), 4.64(d, J=7.8 Hz, 1H, NCHCO), 4.36(m, 3H, PhCHPh+NCH₂CO), 4.18(m, 1H, OCH), 3.97(d, J=5.6 Hz, 2H, OCH₂), 1.18(d, J=6.4 Hz, 3H, CH₃)	489.5[M+H]⁺
Compd.	¹H NMR(400 MHz, CDCl₃), δ	ESI-MS, m/z
4		811.1[M+H]⁺
5	10.11(s, 1H, CHO), 8.33(d,J=8.0 Hz, 1H, CONH), 7.86—6.69(m, 21H, ArH), 6.55(s, 1H, CONH), 6.43(s, 1H, CONH), 4.52—4.15(m, 5H, NCH₂CO+3NCHCO), 3.02—2.89(m, 2H, ArCH₂), 2.39—2.20(m, 4H, CH₂COO+CH₂), 1.41—1.37(m, 21H, 7CH₃)	915.4[M+H]⁺
6		997.2[M+3H]³⁺
7		1296.3[M+3H]³⁺
8		1128.6[M+3H]³⁺
9		1251.2[M+3H]³⁺
10		1138.6[M+3H]³⁺
11		1437.4[M+3H]³⁺
12	6.27(d,J=7.6 Hz, 1H, CONH), 4.54(m, 1H, NCHCO), 2.42(m, 2H, CH₂COO), 2.23(m, 3H, CH₂CO+CCH), 1.93(m, 1H, CCH), 1.60(m, 2H, CH₂), 1.47(s, 9H, 3CH₃), 1.32—1.25(m, 24H, 12CH₂), 0.88(t, J=7.6 Hz, 3H, CH₃)	440.2[M-H]^-

Table 3 Effects of solvents on the yield of intermediate 2

Solvent	HPLC Yield of intermediate 2(%)
Solvent	10 min	2 h
V(Py):V(AcOH)=1:1	91	98
V(Py):V(AcOH)=1:3	87	97
DMF		<1
DMSO		<1
V(H₂O):V(MeCN)=1:1	<1	3.6
V(Et₃N):V(AcOH)=1:3	82	91
AcOH	<1	2.3

Fig.2 HPLC and ESI-MS monitoring of side chain reactionCoupling time/min: a. 10; b. 30; c. acidification time: 30; d. standard sample of liraglutide.

Table 4 Effects of pH values on the yield of coupling intermediate

pH	HPLC yield(%)		pH	HPLC yield(%)
pH	10 min	30 min	pH	10 min	30 min
8	16	27	12	68	91
10	71	93	14	18	30

参考文献 24

[1]	González C., Beruto V., Keller G., Santoro S., Di Girolamo G., Expert Opinion on Investigational Drugs,2006, 15(8), 887—895
[2]	Cao H.Y., Jin X.J., Guo W., Yu Y.X., Shi L.F., Tang Q., Zheng X.F., Chem. J. Chinese Universities,2018, 39(5), 1026—1033
	(曹洪玉, 金晓军, 郭委, 余雅娴, 史龙飞, 唐乾, 郑学仿. 高等学校化学学报, 2018, 39(5), 1026—1033)
[3]	Ren H., Xiong X.H., Jiang T., Zhang Y.D., Wei Z.H., Song X.W., Guan S.W., Wang Y., Wang L.P., Chem. Res. Chinese Universities,2010, 26(4), 604—607
[4]	Goodwin D., Simerska P., Toth I., Curr. Med. Chem.,2012, 19(26), 4451—4461
[5]	Madsen K., Knudsen L.B., Agersoe H., Nielsen P.F., Thøgersen H., Wilken M., Johansen N.L., J. Med. Chem.,2007, 50(24), 6126—6132
[6]	Li B.Q., Peptide Drugs Research and Development, People’s Medical Publishing House, Beijing, 2011, 68—69
	(厉保秋. 多肽药物研究与开发, 北京: 人民卫生出版社, 2011, 68—69)
[7]	Dawson P.E., Muir T.W., Clark-Lewis I., Kent S. B.H., Science,1994, 266(5186), 776—779
[8]	Ma Y., Zhao Y.F., Chinese Science Bulletin,2002, 47(6), 1201—1205
	(麻远, 赵玉芬. 科学通报, 2002, 47(6), 1201—1205)
[9]	Ma Y., Zhao Y.F., Progress in Chemistry,2003, 5, 393—400
	(麻远, 赵玉芬. 化学进展, 2003, 5, 393—400)
[10]	Tam J.P., Xu J.X., Eom K.D., Biopolymers(Peptide Science), 2001, 60(3), 194—205
[11]	Sewald N., Jakubke H.D., Peptides: Chemistry and Biology, Translated by Liu K. L., He J. L., Science Press, Beijing, 2005, 231—232
	(刘克良, 何军林译. 肽: 化学与生物学, 北京: 科学出版社, 2005, 231—232)
[12]	Kemp D.S., Biopolymer, 1981, 20(9), 1793—1804
[13]	Liu C.F., Tam J.P., Proc. Natl. Acad. Sci.,1994, 91, 6584—6588
[14]	Li X.C., Lam H.Y., Zhang Y.F., Chan C.K., Org. Lett.,2010, 12(8), 1724—1727
[15]	Lee C.L., Li X.C., Curr. Chem. Bio.,2014, 22, 108—114
[16]	Lee C.L., Liu H., Wong C.T., Chow H.Y., Li X.C., J. Am. Chem. Soc.,2016, 138, 10477—10484
[17]	Xu C., Lam H., Zhang Y.F., Li X.C., Chem. Commun.,2013, 49, 6200—6202
[18]	Li T.L., Liu H., Li X.C., Org. Lett.,2016, 18, 5944—5947
[19]	Lin D.A., Lam H.Y., Han W.B., Cotroneo N., Pandya B.A., Li X.C., Bio. Med. Chem. Lett.,2017, 27, 456—459
[20]	Lam H.Y., Zhang Y.F., Liu H., Xu J.C., Wong C.T., Xu C., Li X.C., J. Am. Chem. Soc.,2013, 135, 6272—6279
[21]	Wong C.T., Lam H.Y., Song T., Chen G., Li X.C., Angew. Chem.,2013, 52, 10212—10215
[22]	Wong C.T., Lam H.Y., Li X.C., Tetrahedron,2014, 70, 7770—7773
[23]	Lau J.F., Andersen A.S., Bloch P., Lau J., Garibay P.W., Kruse T., Nørby I. S.N., Jessen C.U., Christensen C., Norrild J.C., Semi-recombinant Preparation of GLP-1 Analogues, US 9732137 B2,2015-12-16
[24]	Guryanov I., Bondesan A., Visentini D., Orlandin A., Biondi B., Toniolo C., Formaggio F., Ricci A., Zanon J., Cabri W., J. Pept. Sci.,2016, 22(7), 471—479